Follow on Google News News By Tag * Generic League Market Analysis * Generic League * Generic Pharma * Generic Drugs * Generics Pharmaceutical Products * Generics R D * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News |  Generic League - Market Analysis and Forecasts, 2007-2012, 2017 & 2022Visiongain is proud to announce the release of the brand new report "Generic League". In 2006, the global generics market attained strong revenues of approximately $65bn, up by 12% in comparison with $58bn in 2005.
By: Visiongain Ltd. The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality. In 2006, the global generics market attained strong revenues of approximately $65bn, up by 12% in comparison with $58bn in 2005. However, during the same period, the Top Ten leading generic suppliers generated total revenues of $27.9bn, up by a growth rate of 34%. The Top Five Companies within that sector experienced significant revenues, with market growth largely driven by significant commercial activities, key Mergers and Acquisition (M&A) and launch of new product in the leading markets. In light, of the significant number of proprietary branded pharmaceuticals approaching patent expiration in the near-term, visiongain predicts that the generic market is set to experience further market expansion during the forecast period. Visiongain also predicts that by 2023, the Top Ten leading generic suppliers will experience CAGR of 7%. That significant CAGR, will be driven by generic versions of leading blockbuster drugs presently estimated at $100bn, nearing patent expiration during 2008-2012. Prominently, amongst the products with looming patent expirations are drugs such as: • Pfizer's Lipitor • AstraZeneca's Nexium • Bristol Myers Squib's Plavix • Pfizer's Norvasc • Lilly's Zyprexa • Janssen's Risperdal • Wyeth's Effexor In 2007, a total of 14 drugs came of patent in the US market. In 2008, a total of 14 drugs are expected to lose patent protection in the US market. In 2009, five drugs are predicted to becoming off-patent in the US market. On the 24 of March 2010, the world's highest selling drug, Pfizer's Liptor will come off-patent in the US. In the EU market, UCB's Keppra and four other medicines are expected to lose patent protection. In 2011, 10 major drugs in the US market will also become exposed to generic competition. An estimated 11 drugs will experience generic competition in the EU market during the same year. Significant among these drugs will be Lipitor and Zyprexa. Moreover, the generic market is projected to further expand through the growing uptake of biogeneric/ Visiongain’s market analysis forecast a-to- be lucrative era during the mid-term of our forecast where we believe, the Top Ten generic suppliers will see strong sales growth leveraged through licensing of new products. With Top Ten company-by-company forecast focus on regions: Asia • Teva (Asia/ Israel) Europe • Actavis (Finland) • Merck KGaA (Germany) • Ratiopharm (Germany) • Sandoz (Switzerland) • Stada (Germany) North America • Apotex (Canada) • Barr (US) • Mylan (US) • Watson (US) This report includes detailed five-year forecasts over the period 2007-2012, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets. Why You Must Buy This Report: This report features in-depth primary research, tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of operations of Top Ten companies that has driven their corporate growth in recent times. In addition, the report sheds significant emphasis on key strategies that will drive year-on-year sales growth of their leading products. Despite the lucrative opportunities presented to the leading companies through patent expirations, the visiongain reports analyses the key battles that the leading Top Ten generic companies will face during the same period. What questions does the report answer? • Who are the generic market leaders? • Which regions dominate the generic market? • Which of the Top Ten companies conducted key M&As to bolster product pipeline? • Have the M&As been successful in expanding product range? • Is the cost of branded medicines justifiable by Big Pharma? • How will the Top Ten account for future revenues? • Will the Top Ten continue to experience market share expansion? • How will the Top Ten overcome the legal battles? • Are the legal battles really worth the cost of the generic medicines? • What direction is Biogenerics marketing taking? • Will the EU regulatory bodies narrow the generic gap between the US? • Will the Top Ten themselves be acquired under mounting pressure of strong market competitions? • Will the rising cost of R&D, deter the Top Ten from investing? • Are the voices of managed care organisations (MCOs), healthcare providers and payers driving down sales of Big Pharm’s blockbusters? • Is the EU a “nice-to-operate- Companies Listed Abbott Laboratories Abrika Abz Pharma Actavis Active Biotech Akzo Nobel Alcon Labs Allergan Alphapharm Alza Amgen Amide Anchen Pharmaceuticals Andrx Apotex Apothecon AstraZeneca Aventis Azupharma Balkanpharma BASF Pharma Bayer Bioceuticals Arzneitmittel Biochemie Biogen Idec Bioval Boehringer Ingelheim Bristol- Myers Squibb Cajavec Cell Pharma Celltech Cephalon Cipla Colotech Croma CT Arzneimittel Daiikyi Sankyo Dey Duramed Durascan Eisai Elan Eli Lilly Elite Eon Labs Esteve Quimica S.A Eurogenerics FEI Women's Health LLC Ferd Schulze Forum Bioscience Geneva Pharmaceuticals Genevar Genpharm GlaxoSmithKline GlycoSciences Helvepharm Hemovet Hexal AG Hospira IMPAX IntelliPharmaCeutics Ivax Janssen Johnson & Johnson King Pharmaceuticals Labinca Lagap Pharmaceuticals Lareq Pharma Lundbeck Magnafarma BV Markiz Martec Matrix Docpharma Matrix Laboratories Meph Merck & Co Merck Génériques Merck KGaA Merckle Multipharma Mylan Mylan Technologies Inc NM Pharma Nycomed Organon Ortho Biotech ParaGard Penederm Pfizer Pharmacia PharmaCoDane Aps Plantex Pliva PriceWaterHouseCooper Proctor & Gamble Progen Biotechnik Quimica Farmaceutica Ratiopharm Roche Rolab Sabex Sandoz Sanmar Sanofi-Aventis Savient Scandharm Schering-Plough Sekhsaria Chemical Limited Serono Servipharm Shire Sigma Sindan Solvay Somerset Pharma Stada Takeda Technilab Pharma Teva Topgen UCB UDL Laboratories US Department of Defence Ventiv Health Warner Chilcott Watson Weizmann Institute of Science WHO Wyeth Xanodyne Zambon Zio Zdorovje Visiongain ltd. 4th Floor, BSG House, 226 236 City Road, London EC1V 2QY United Kingdom Telephone: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9930 info@visiongainglobal.com Or Visit at: http://www.visiongain.com/ Or http://www.visiongain.com # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
